Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493067 | 0.84 | ALDH1A1 (0.37) | KMT2AMEN1CHRM1CACNA1ACACNA2D1 | |
| SCHEMBL5048028 | 0.83 | ALDH1A1 (0.43) | KMT2AMEN1CACNA2D1CACNB1 | |
| SCHEMBL3495205 | 0.81 | HMOX2 (0.41) | — | |
| SCHEMBL28429419 | 0.76 | KMT2A (0.40) | KMT2AMEN1TACR1CACNA1ACACNA2D1 | |
| SCHEMBL4899270 | 0.75 | KMT2A (0.56) | KMT2AMEN1CHRM1CACNA2D1CACNB1 | |
| SCHEMBL649412 | 0.75 | GPR119 (0.38) | KMT2AMEN1CHRM3 | |
| SCHEMBL4279035 | 0.75 | GPR119 (0.44) | KMT2AMEN1CHRM1CHRM3 | |
| SCHEMBL20141312 | 0.73 | MEN1 (0.34) | KMT2AMEN1TACR1CHRM3 | |
| SCHEMBL17781830 | 0.72 | KMT2A (0.41) | KMT2AMEN1CHRM3 | |
| SCHEMBL911824 | 0.70 | ALDH1A1 (0.45) | KMT2AMEN1CACNA2D1CACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | KMT2A 952/4885MEN1 750/4885CHRM1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.